Company: THC
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001193125-25-079143
Chunk: 22

Company: TENET HEALTHCARE CORP
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 22
---
 only non-independentdirector who serves on our Board is our Chairman and Chief Executive Officer, Dr. Sutaria. In making its independence determinations, the Board broadly considers all relevant facts and circumstances and focuses on the organizations with which each director has an affiliation. If a director or member of the director’s immediate family has a material relationship with the Company, the Board reviews the interest to determine if it would preclude an independence determination. The Audit Committee, the Human Resources Committee (HR Committee) and the Governance Committee are composed exclusively of independent directors as required by the NYSE. Additionally, the Environmental, Social and Governance (ESG) Committee and the Quality, Compliance & Ethics Committee (QCE Committee) are composed exclusively of independent directors. All directors serving on the Audit Committee meet the more stringent independence standards for audit committee members required by the SEC, and all directors serving on the HR Committee meet the more stringent independence standards for compensation committee members required by the NYSE.

| 2025 PROXY STATEMENT |     | 23 |

Corporate Governance and Board Practices Commitment to Sound Corporate Governance Policies and Practices Tenet is committed to maintaining corporate governance policies and practices that protect the long-term interests of our shareholders and promote Board and management accountability. Our Board recognizes that this requires us to review and refine our corporate governance practices on an ongoing basis to continue to align with evolving market practices and the best interests of our Company and shareholders. Some of our key corporate governance policies and practices include:

| SHAREHOLDER RIGHTS |     | •  Annual election of directors •  Shareholder right to call special meetings at 25% threshold •  Proxy access with market standard terms •  One-year limit on “poison pills” unless approved by shareholders •  Single class of stock with equal voting rights •  Majority vote standard and director resignation policy in uncontested elections |

| BOARD PRACTICES |     | •  All directors are independent other than our Chief Executive Officer •  Experienced Board with varied backgrounds •  Independent Lead Director with clearly defined responsibilities •  Commitment to Board refreshment practices •  Self-evaluation of all directors using third-party facilitator •  Board oversight of political contributions •  Regular executive sessions of independent directors for Board and committee meetings •  Ongoing engagement with shareholders •  Increased focus on ESG matters